<< Back To Search

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This study is testing whether a medicine called iberdomide can be given to people after a certain type of cancer treatment to see if it is safe and effective. The medicine will be taken once a day for 21 days out of each 28-day cycle, until either the cancer comes back or there are bad side effects. Up to 38 people will participate in the study to see if it is worth doing a bigger study later on.
*Third Opinion AI Generated Synopsis

Trial Summary
This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Treatment will continue until disease progression or toxicity. The results from this study will inform the feasibility of pursuing a study comparing iberdomide to lenalidomide maintenance post-ASCT.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?